Kolon TissueGene, Inc.
Clinical trials sponsored by Kolon TissueGene, Inc., explained in plain language.
A biopharmaceutical company developing cell and gene therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Could a single injection fix your aching back?
Disease control Not yet recruitingThis early-stage trial tests a new cell-based injection called TG-C for people with long-term lower back pain due to degenerative disc disease. 24 adults aged 22 to 70 will receive either a high, mid, or low dose of TG-C injected into the spinal disc, or a sham (fake) injection. …
Phase 1 • Sponsor: Kolon TissueGene, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could a single injection fix early hip arthritis?
Disease control Not yet recruitingThis study tests an experimental injection called TG-C for people with early hip osteoarthritis. The injection contains cells that release a growth factor to help repair damaged cartilage. 255 adults will receive either TG-C or a placebo, and researchers will track pain and hip f…
Phase 2 • Sponsor: Kolon TissueGene, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC